Repurposing CD8<sup>+</sup> T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

Gujar, Shashi; Pol, Jonathan G; Kim, Youra; Kroemer, Guido

Repurposing CD8⁺ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

Gujar, Shashi; Pol, Jonathan G; Kim, Youra; Kroemer, Guido.

Affiliation

Gujar S; Department of Pathology, Dalhousie University, Halifax, NS, Canada.
Pol JG; Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.
Kim Y; Department of Biology, Dalhousie University, Halifax, NS, Canada.
Kroemer G; Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.

Oncoimmunology ; 9(1): 1794424, 2020 07 16.

Article in En | MEDLINE | ID: mdl-32923158

Subject(s)

CD8-Positive T-Lymphocytes/transplantation; COVID-19/immunology; Immunotherapy/methods; Neoplasms/therapy; SARS-CoV-2/immunology; Antibodies, Viral/immunology; Antibodies, Viral/metabolism; CD8-Positive T-Lymphocytes/immunology; CD8-Positive T-Lymphocytes/metabolism; COVID-19/blood; COVID-19/epidemiology; COVID-19/prevention & control; COVID-19 Vaccines/administration & dosage; Host Microbial Interactions/immunology; Humans; Immunologic Memory; Neoplasms/immunology; Pandemics

Key words

CD8+ T cell epitopes; SARS-CoV-2; antigen spreading; antiviral immunity; cancer immunotherapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: CD8-Positive T-Lymphocytes / SARS-CoV-2 / COVID-19 / Immunotherapy / Neoplasms Limits: Humans Language: En Journal: Oncoimmunology Year: 2020 Document type: Article Affiliation country: Canada

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google